Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Eficacia del sistema de estimulación modular EMPOWER™ y el DAI subcutáneo EMBLEM™ para comunicar la estimulación antitaquicardia (MODULAR ATP)

9 de noviembre de 2026 actualizado por: Boston Scientific Corporation

The MODULAR ATP Clinical Study is designed to demonstrate safety, performance, and effectiveness of the Modular Cardiac Rhythm Management (mCRM) Therapy System.

Descripción general del estudio

Estado

Activo, no reclutando

Condiciones

Intervención / Tratamiento

Descripción detallada

The MODULAR ATP Clinical Study will enroll subjects with a standard Implantable Cardioverter Defibrillator (ICD) indication applying international practice guidelines, as well as those who already have an implanted S-ICD System and satisfy the inclusion criteria for this study, while not meeting any exclusion criteria. Subjects will be followed for at least 6 months following mCRM Therapy System implantation.

Tipo de estudio

Intervencionista

Inscripción (Actual)

297

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • Linz, Austria
        • Kepler Universitaetsklinikum
      • Québec, Canadá
        • Institut Universitaire de Cardilogie et Pnuemologie de Quebec (IUCPQ)
    • Quebec
      • Montreal, Quebec, Canadá, H1T 1C8
        • Institut de Cardiologie de Quebec (Montreal Heart)
      • Prague, Chequia
        • Na Homolce Hospital
      • Barcelona, España, 08036
        • Hospital Clinic of Barcelona
    • Arizona
      • Phoenix, Arizona, Estados Unidos, 85006
        • Banner University Medical Center Phoenix
      • Scottsdale, Arizona, Estados Unidos, 84258
        • Scottsdale Healthcare - Shea
    • Arkansas
      • Jonesboro, Arkansas, Estados Unidos, 72401
        • Arrhythmia Research Group
    • Florida
      • Orlando, Florida, Estados Unidos, 32803
        • AdventHealth Orlando
    • Georgia
      • Atlanta, Georgia, Estados Unidos, 30308
        • Emory University Hospital
    • Kentucky
      • Lexington, Kentucky, Estados Unidos, 40503
        • Baptist Health Lexington
    • Minnesota
      • Rochester, Minnesota, Estados Unidos, 55905
        • Mayo Clinic
    • New Jersey
      • Camden, New Jersey, Estados Unidos, 08103
        • Cooper Hospital - University Medical Center
    • New York
      • Manhasset, New York, Estados Unidos, 11030
        • Northwell University Hospital
      • New York, New York, Estados Unidos, 10029
        • Mount Sinai Medical Center
    • Ohio
      • Cleveland, Ohio, Estados Unidos, 44195
        • Cleveland Clinic
      • Columbus, Ohio, Estados Unidos, 43210
        • Ohio State University Medical Center
      • Columbus, Ohio, Estados Unidos, 43214
        • Ohio Health Research Institute
    • Pennsylvania
      • Hershey, Pennsylvania, Estados Unidos, 17033
        • Penn State Health Milton S. Hershey Medical Center
      • Philadelphia, Pennsylvania, Estados Unidos, 19104
        • Hospital of the University of Pennsylvania
    • Tennessee
      • Chattanooga, Tennessee, Estados Unidos, 37403
        • Erlanger Medical Center
    • Virginia
      • Norfolk, Virginia, Estados Unidos, 23507
        • Sentara Norfolk General
    • Washington
      • Seattle, Washington, Estados Unidos, 98195
        • University of Washington Medical Center
      • Grenoble, Francia
        • CHU Grenoble - Hospital Michallon
      • Lille, Francia, 59000
        • CHRU de Lille
      • Nantes, Francia
        • CHU de Nantes-Hopital Laennec
      • Paris, Francia
        • Hospital European Georges-Pompidou
      • Brescia, Italia
        • Spedali Civil di Brescia
      • Cotignola, Italia
        • Maria Cecilia Hospital SPA
      • Naples, Italia, 80131
        • AZ Osp Monaldi
      • Pisa, Italia, 56126
        • Azienda Ospedaliero Universitaria Pisana
      • Amsterdam, Países Bajos
        • Amsterdam University Medical Center
      • Nieuwegein, Países Bajos
        • St. Antonius Ziekenhuis
      • Rotterdam, Países Bajos, 3015 CE
        • Erasmus MC University Medical Center
      • Leeds, Reino Unido, LS1 EX
        • The General Infirmary
      • Liverpool, Reino Unido, L14 3PE
        • Liverpool Heart and Chest Hospital
      • Manchester, Reino Unido, M13 9WL
        • Manchester Heart Center
      • Southampton, Reino Unido
        • Southampton University Hospital

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Patient who meets Class I, IIa, or IIb guideline ICD indications[i],[ii], or who has an existing TV-ICD[iii] or S-ICD[iv]

  • Patient who is deemed to be at risk for MVT based on at least ONE of the following:

    • History of Non-Sustained MVT with LVEF ≤ 50%
    • History of sustained VT/VF (secondary prevention) with LVEF ≤ 50% or significant cardiac scar*
    • History of syncope deemed to be arrhythmic in origin
    • History of ischemic cardiomyopathy with LVEF ≤35%
    • History of non-ischemic cardiomyopathy with LVEF ≤35% and significant scar*
  • Patient who is willing and capable of providing informed consent (which is not to include the use of a legally authorized representative (LAR) for documentation of informed consent) and participating in all testing associated with this investigation at an approved study site and at the intervals defined by this protocol

  • Patient who is age 18 years or above, or of legal age to give informed consent specific to state and national law

Exclusion Criteria:

  • Patient with an ongoing complication due to Cardiac Implantable Electronic Device (CIED) infection or CIED explant

  • Transvenous lead remnants within the heart from a previously implanted CIED (Note: transvenous lead remnants outside the heart (e.g., in the SVC) are allowed)

  • Patient with a known LA thrombus

  • Patient with a ventricular arrhythmia due to a reversible cause

  • Patient indicated for implantation of a dual chamber pacemaker or cardiac resynchronization therapy (CRT)

  • Patient with another implanted medical device that could interfere with implant of the leadless pacemaker, such as an implanted inferior vena cava filter or mechanical tricuspid heart valve

  • Patient requires rate-responsive pacing therapy

  • Patient is entirely pacemaker-dependent (defined as escape rhythm ≤ 30 bpm)

  • Patient with Acute Coronary Syndrome (i.e. Acute Myocardial Infarction, Unstable Angina) within 40 days

  • Inability to access femoral vein with a 21-French or larger inner diameter introducer sheath due to known anatomy condition, recent surgery, and/ or other relevant condition

  • Patient who has an active implanted electronic medical device intended for chronic use concomitantly with the study system, such as a left ventricular assist device (LVAD). Note that a temporary pacing wire is allowed.

  • Patient with known or suspected sensitivity to Dexamethasone Acetate (DXA)

  • Patient with a known cardiovascular anatomy that precludes implant in the right ventricle

  • Patient with a known allergy to any system components

  • Patient with a known or suspected intolerance to S-ICD conversion testing, based on physician discretion

  • Patient is not likely to have meaningful survival** for at least 12 months (documented or per investigator's discretion)

  • Patient is enrolled in any other concurrent study. Co-enrollment into other studies such as observational studies/ registries needs prior written approval by BSC. Local mandatory governmental registries are accepted for co-enrollment without approval by BSC.

  • Patient who is a woman of childbearing potential who is known to be pregnant at the time of study enrollment (method of assessment upon investigator's discretion)

    [i]Al-Khatib, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. (2018); 138:e272-e391.

[ii] 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). European Heart Journal (2015) 36, 2793-2867.

[iii] TV-ICD system is expected to be fully explanted during or prior to full Coordinated System implant

[iv] Potential subjects with a Model 1010 S-ICD Pulse Generator are only eligible for MODULAR ATP if they are getting upgraded to Model A209, A219 or future BSC S-ICD Pulse Generator; Patients with an existing S-ICD PG subject to the electrical overstress field action are only eligible for MODULAR ATP if they are getting a new BSC Model A209 or A219, or future BSC S-ICD Pulse Generator

*Significant cardiac scar is defined as a scar involving at least one ventricular myocardial segment (i.e., basal infero-septum) as identified in the official findings of a cMRI, or nuclear viability study, or echo report by the interpreting radiologist/ cardiologist who is not affiliated with the study

**meaningful survival means that a patient has a reasonable quality of life and functional status

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: MODULAR ATP Study Participants

All subjects that signed the informed consent were included.

Patients consented to receive the mCRM Therapy System which consists of the EMPOWER Leadless Pacemaker and an EMBLEM S-ICD upgraded with investigational firmware.

Communication testing between S-ICD and LCP in 4 body postures as well as required electrical testing.

Otros nombres:
  • Comunicación de S-ICD a marcapasos cardíaco sin cables (LCP)

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Safety Endpoint 1: Percentage of Subjects Without Major EMPOWER MPS System- or Procedure-Related Complications Through 6 Months
Periodo de tiempo: Implant through 6 Months Post-Implant

Major EMPOWER MPS System- and Procedure-related Complication-Free Rate Subjects will be assessed for safety issues related to the procedure or system through 6 months post implant

Implant through 6 Months Post-Implant
Safety Endpoint 2: Percentage of Subjects Without Major EMPOWER MPS System- or Procedure-Related Complications Through 12 Months
Periodo de tiempo: Implant through 12 Months Post-Implant

Major EMPOWER MPS System- and Procedure-related Complication-free Rate

Subjects will be assessed for safety issues related to the procedure or system through 12 months post implant

Implant through 12 Months Post-Implant
Primary Effectiveness Endpoint 1: Percentage of Body Postures With Communication Success Between the S-ICD and EMPOWER PG
Periodo de tiempo: At the 6 Month Follow-up

Communication Success between the S-ICD and EMPOWER PG

Data from subjects will be assessed for effectiveness of communication between S-ICD and the EMPOWER PG by evaluating if a paced beat is present during communication testing in four postures: upright, supine, and right and left side.

At the 6 Month Follow-up
Primary Effectiveness Endpoint 2: Percentage of Subjects Classified as a Pacing Capture Threshold (PCT) Responder
Periodo de tiempo: At the 6 Month Follow-up

Proportion of Subjects with Adequate Pacing Capture Threshold

Effectiveness will be confirmed by evaluating the percentage of subjects considered to be a PCT Responder, defined as a subject with a PCT measurement of ≤ 2.0 V @ 0.4 ms pulse width

At the 6 Month Follow-up

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Secondary Effectiveness Endpoint: Subject-specific Slope of EMPOWER PG Sensor-Indicated Rate to the Subject's Workload on Treadmill Test
Periodo de tiempo: At the 3 Month Visit

Metabolic-Chronotropic Relation Slope (MCR Slope) from the Kay-Wilkoff Model

Using the Kay-Wilkoff model, data will be assessed to evaluate the proportionality of the EMPOWER PG's sensor-indicated rate to the subject's workload during the treadmill test

At the 3 Month Visit
Secondary Safety Endpoint
Periodo de tiempo: Implant through 2 years post-implant

All-Cause Survival; data not reported as it is still being collected

Implant through 2 years post-implant

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Investigador principal: Reinoud Knops, MD, PhD, Amsterdam University Medical Centre
  • Investigador principal: Lluis Mont, MD, PhD, Hospital Clinic, University of Barcelona
  • Investigador principal: Vivek Reddy, MD, The Mount Sinai Hospital
  • Investigador principal: Michael Lloyd, MD, Emory University

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Publicaciones Generales

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

20 de julio de 2021

Finalización primaria (Actual)

6 de mayo de 2024

Finalización del estudio (Estimado)

31 de diciembre de 2030

Fechas de registro del estudio

Enviado por primera vez

8 de marzo de 2021

Primero enviado que cumplió con los criterios de control de calidad

12 de marzo de 2021

Publicado por primera vez (Actual)

15 de marzo de 2021

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

12 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

9 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • C1907

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Descripción del plan IPD

There is no plan to share IPD with other researchers in this study.

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

Sí

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .